FIRST AIRED: December 4, 2017

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



>> The Philippines government on Monday ordered an investigation into a vaccine given to hundreds of thousands of children for dengue. The probe comes on the heels of last week's decision to halt it's use. After French drug company, Sanofi said new findings showed Dengvaxia, the first ever vaccine approved for dengue could actually worsen the disease in some cases.
>> In individuals who have not been previously infected by dengue virus, there is an increased risk of hospitalization for dengue and severe dengue. Predominantly grade 1 or 2 dengue hemorrhagic fever.>> But the company stopped short of saying why it did not take action after a report by the World Health Organization in mid 2016 flagged the exact same risk.
As public concern mounts, a non-governmental organization said it had been told of three deaths of children in the Philippines. From Dengvaxia, a local Senator adding he had heard of two. Sanofi says it is not aware of any reported deaths related to the vaccine. More than 730,000 children aged nine and over in the Philippines have received one dose of the vaccine as part of a $70 million program.
Dengue is mosquito-born tropical disease spreading rapidly in many parts of the world, killing about 20,000 people a year and infecting hundreds of millions.